Top News
- AstraZeneca's Wainua fails to reduce cardiovascular deaths in Phase 3 trial, missing primary endpoint
Stock dropped on the setback; trial assessed the drug's ability to prevent heart-related mortality in high-risk patients.
- Novartis acquires UK cancer biotech for $1.5B, expanding oncology pipeline with Imperial College spinout
Target spun from Imperial College and Francis Crick Institute in 2019; adds to Novartis's recent M&A activity in precision oncology.
- Revolution Medicines says sale is not a priority, rebuffing takeover speculation after Merck's failed $32B bid
Merck's unsuccessful approach signals appetite for the RAS-oncology specialist; company reaffirms independence strategy.
- EU antitrust authorities launch probe into Sanofi over alleged misleading campaign against rival flu vaccine maker
Competition watchdog examining whether group implemented 'misleading' campaign affecting market competition in vaccines segment.
- UK launches national dementia registry to accelerate clinical trial recruitment and life sciences investment
Platform aims to improve patient access to experimental treatments while boosting domestic biotech competitive positioning.
- Eli Lilly launches AI drug-discovery platform with small biotech collaborators, leveraging weight-loss franchise cash
Move signals major pharma's shift toward open-innovation model for computational drug design amid GLP-1 revenue windfall.
Biopharma M&A hits record $170.1B in first half of 2026, surpassing prior-year full totalJune deal value reached $25.7B; 2025 full-year total was $139.35B.
- AbbVie acquires Apogee Therapeutics for $10.9B to expand inflammatory disease portfolio
Deal marks AbbVie's largest acquisition in over five years amid heightened pharma M&A activity.
Danaher's Leica Biosystems acquires Statlab Medical Products to expand anatomical pathology diagnostics portfolioDeal expands consumables and instruments offerings; financial terms undisclosed.
GSK halts camlipixant development after mixed Phase 3 data in refractory chronic cough, shelving $2B acquisitionThird failure in P2X3 antagonist class; clears path for Trevi's Haduvio (nalbuphine ER) after positive Phase II results.
More: BioWorld
Insmed's TPIP maintains pulmonary arterial hypertension benefits in open-label extension studyOnce-daily inhalation powder shows sustained efficacy in treated arm; potential Phase III catalyst.
FDA grants traditional approval to Novartis's Fabhalta to slow kidney function decline in primary IgANFirst and only approved therapy targeting IgA nephropathy; addresses high-unmet-need rare kidney disease with significant progression risk.
NICE recommends Bayer's Kerendia for NHS patients with chronic heart failure, expanding eligible populationDrug covers both preserved and mildly reduced ejection fraction phenotypes; NHS coverage decision follows positive appraisal.
- Jasper Therapeutics to acquire immune-focused Kira Pharmaceuticals for $132 million
Deal includes concurrent licensing agreement with Mirador; aims to rebuild Jasper after recent setbacks eroded most shareholder value.
More: BioPharma Dive
Mirador Therapeutics licenses Kira's long-acting anti-C5a antibody KP-301 for ANCA-associated vasculitis treatmentKP-301 designed for reduced dosing frequency compared to existing complement inhibitors in rare systemic vasculitis.
Arbutus, Sanofi escalate mRNA patent disputes; InnoCare's TYK2 inhibitor advances in developmentNew lawsuits expand ongoing COVID vaccine technology patent conflicts between major players.
Valerio Therapeutics and Abivax establish exclusive R&D collaboration to develop immune-mediated inflammatory disease therapeuticsBinding term-sheet establishes collaboration framework; financial terms and therapeutic focus areas not yet disclosed.
- Merck KGaA to acquire Bio-Techne for $11.3B, marking largest life-sciences deal in over a decade
German conglomerate's biggest acquisition since 2012 expands its portfolio in diagnostics, research tools, and protein-science instrumentation.
DNA Script expands DNA synthesis platform into India via distribution deal with Imperial Life SciencesSYNTAX platform now accessible to Indian researchers and biotech companies through ILS partnership.
Sonothera uses ultrasound to deliver genes into cells, targeting muscular dystrophy and other genetic diseasesThe approach could overcome major barriers in gene therapy delivery if preclinical claims hold up in human studies.
Novo Nordisk secures European approval for oral Wegovy, moving ahead of Lilly in obesity pill raceFirst-mover advantage in oral GLP-1 market as competition with Lilly's orforglipron intensifies.
- Dassault Systèmes in talks to acquire clinical trial software company ArisGlobal for ~$2B
Deal would expand French conglomerate's life sciences portfolio; ArisGlobal backed by Swedish buyout group Bridgepoint.
Germany doubles patented drug rebate mandate to 15.5% and freezes prices through 2030 as part of healthcare cost-control legislationVaccine rebates set at 9%; industry argues move threatens R&D investment in Europe's largest pharma market.
- CDC and CMS consider updating CLIA regulations for first time in nearly 40 years to reflect modern lab testing advances
Clinical Laboratory Improvement Amendments enacted in 1988; update would modernize oversight of diagnostic testing technologies.
Abbott raises FY2026 EPS guidance to $5.45–$5.60 on strong medical devices, CGM growthQ2 beat driven by continuous glucose monitoring and electrophysiology expansion; cancer diagnostics also contributed.